Candidate HIV Vaccine Passes Key Early Test


In humans, the vaccine was safe and produced antibody responses and T-cell responses, and in monkeys, the vaccine not only produced similar immune responses, but protected against a type of simian-human immunodeficiency virus (SHIV), reported Dan H. Barouch, MD, of Beth Israel Deaconess Medical Center in Boston, and colleagues.

Only one vaccine has ever shown evidence of protecting against HIV. Implementation of even a moderately effective HIV vaccine together with the existing HIV prevention and treatment strategies is expected to contribute greatly to the evolving HIV/AIDS response. The potential development of this HIV vaccine, which is entirely safe for humans, is quite promising, and the next phase would be to test it on 2,600 women in southern Africa.

Now published its key data on early stages, explained in the company Johnson & Johnson, whose daughter Janssen pharmaceuticals has developed a vaccine. Despite unprecedented advances in HIV treatment and prophylaxis, the number of people living with HIV infection continues to increase worldwide.

"This study demonstrates that the mosaic Ad26/Ad26 plus gp140 vaccine candidate induced robust and comparable immune responses in human and monkeys", said Barouch, who is also Professor of Medicine at Harvard Medical School. This invention was a real challenge for scientists, because of this virus many strains.

A vaccine is a vital weapon in the war against the virus, which infects an 1.8 million people each year.

In addition to showing successful immune responses in the human patients, the vaccine was also shown to fend off a similarly risky immunodeficiency virus in 67% of monkeys who received the treatment.

Sebastian Vettel wins British GP, Lewis Hamilton second at Silverstone
Brendon Hartley's wretched Formula One run has continued after he failed to finish the British Grand Prix at Silverstone . Mercedes' errors cost both Hamilton and Bottas in the Austrian GP the week before when neither finished.

Also, the vaccine candidate provided 67 percent protection against infection with an HIV-like virus in monkeys, according to the study.

The APPROACH trial recruited 393 healthy, HIV-uninfected adults (aged 18-50 years) from 12 clinics in east Africa, South Africa, Thailand, and the U.S. between February 2015 and October 2015. The participants were randomly assigned one of seven combinations of a vaccine, while one group was given a placebo.

Participants in the research were selected from 12 clinics in East Africa, South Africa, Thailand, and the USA. They were administered 4 injections over a period of 48 weeks and their immune system response was noted. Scientists must await the results of this trial find out whether the vaccine cannot only provoke an immune response, but actively protect against HIV.

There has been a four decades long challenge to develop a vaccine against the deadly HIV virus that causes AIDS.

A new HIV vaccine is inspiring "cautious" hope in scientists after it passed human trials with "promising" results. Though the vaccine triggered a response in the immune system of the people who took it, it is not clear if this would be enough to fight off the virus and prevent infection. They also note that there is no definitive immunological measurement that is known to predict protection against HIV-1 in humans.